SBTX SkinBioTherapeutics plc

0.0527USD4.000 GBp · LSE-5.88%Mkt Cap: 13.65M USDP/E: —

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, a…

Key Statistics

Company
Market Cap13.65M USD
Enterprise Value10.77M USD
Revenue (TTM)6.88M USD
Gross Profit3.77M USD
Net Income (TTM)-916.86K USD
Revenue/Share0.03 USD
Last Price0.0527 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees41
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BF33H870
Valuation
P/E (Trailing)—
P/E (Forward)21.16
PEG—
EV/EBITDA-11.14
EV/Revenue1.57
P/S1.98
P/B1.29
EPS (TTM)0.00 USD
EPS (Forward)0.0025 USD
52W Range
0.05270% of range0.3029
52W High0.3029 USD
52W Low0.0527 USD
Profitability
Gross Margin61.65%
Oper. Margin-20.95%
EBITDA Margin-14.05%
Profit Margin-15.01%
ROE-7.39%
ROA-5.74%
ROIC-19.29%
ROCE-10.47%
Growth
Revenue Growth37.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.63M USD
CapEx (TTM)209.15K USD
FCF Margin-26.90%
FCF Yield-13.57%
Net Debt-2.88M USD
Net Debt/EBITDA2.98
Net Debt/FCF—
Balance Sheet
Debt/Equity0.11
Current Ratio6.14
Quick Ratio4.96
Book Value/Sh0.04 USD
Cash/Share0.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.3819 USD
Upside (mean)+625.0%
Target Range0.3819 USD – 0.3819 USD
# Analysts1
Ownership
Shares Out.259.17M
Float116.00M
Insiders41.14%
Institutions13.41%
Technical
SMA 500.0792 (-33.5%)
SMA 2000.0963 (-45.3%)
Beta0.08
S&P 52W Chg12.00%
Avg Vol (30d)296.43K
Avg Vol (10d)439.15K
Technical Indicators
RSI (14)18.1
MACD-0.4810
MACD Signal-0.4647
MACD Hist.-0.0163
BB Upper0.0780 USD
BB Middle0.0657 USD
BB Lower0.0533 USD
BB Width37.64%
ATR (14)0.0069 USD
Vol Ratio (20d)0.43x

About SkinBioTherapeutics (LON: SBTX)

›

SkinBioTherapeutics (LON: SBTX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 41 employees.

The shares were at 4.000 GBp on 19 November 2026, down 75.0% over 52 weeks. Its 52-week range is 4.000 GBp to 23.00 GBp, and it trades at the bottom of that range.

Its market capitalisation is 10.37M GBP.

SkinBioTherapeutics reports return on equity of -7.4%, an operating margin of -21.0% and revenue up 37.4% year over year.

It holds more cash than debt, a net cash position of 2.19M GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.